Reverse-Switching OTC Antimicrobials Could Cost Europe An Additional €10bn Per Year

Over five years, the cost of the European Commission's proposal could exceed a total €50bn, finds a study by IQVIA commissioned by the AESGP.

AR
European policy targeting AMR could be very costly • Source: Shutterstock

Making commonly used antimicrobial products like athlete’s foot, vaginal thrush treatments and cold sore creams available only with a prescription in Europe could cost the region close to €10bn ($10.6bn) a year in additional health expenses, according to IQVIA.

Over five years, this cost – which stems primarily from increased doctor’s visits (59m extra per year) and productivity losses – to Europe’s health system could exceed a total of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Europe

Self-Care Must Be Central To NHS Reform, Says UK Industry And Pharmacy Alliance

 
• By 

Ahead of a soon to be released 10-Year Health Plan for the English NHS, an alliance including PAGB calls for self-care to be “clearly recognised and supported through concrete policies that reflect its vital role in achieving the plan’s goals.”

Value Of Consumer Wearables Within The Clinic Currently Unknown, Says Cardiologist

 

“It’s quite likely [consumer wearable manufacturers] are changing the sensitivity and specificity based on consumer feedback, but not for medical reasons,” said Dipak Kotecha, a University of Birmingham professor of cardiology. Often, self-reported performance evidence from manufacturers is “low quality and biased.”

EU Parliament Calls For Review Of Wastewater Directive’s Impact On Pharma Sector

 
• By 

At a recent plenary session the European Parliament adopted a resolution calling on the European Commission to “conduct a new and comprehensive assessment” of the impact of the revised Urban Wastewater Treatment Directive on the pharmaceutical sector.

Supplementation Unlikely To Help With Hereditary Hair Loss, Says German Agency

 
• By 

Germany’s Federal Institute for Risk Assessment says that there is "no evidence that people with androgenetic alopecia have special dietary needs or a special nutrient requirement.”

More from ESG

EU Parliament Agrees To Postpone Due Diligence And Sustainability Reporting Rules

 
• By 

Speaking at a recent AESGP webinar, sustainability expert Onur Durmus called the the European Commission’s “Omnibus” proposals - designed to simplify ESG reporting rules and recently supported by EU Parliament - a “positive development” for the European consumer health industry.

AESGP Slams ‘Deeply Concerning And Discriminatory’ EU Wastewater Directive

 
• By 

“Protecting the environment is a shared responsibility. It is unfair to expect only two sectors to fund wastewater treatment modernization and operation,” argues AESGP director general Jurate Švarcaite.

‘We All Have To Start Somewhere’: How Retailers Are Shaping Perrigo’s Climate Ambitions

 
• By 

Perrigo's retail customers are expecting real "net zero" progress from consumer health manufacturers, which is in turn driving the firm's sustainability ambitions and expectations from their own suppliers, Perrigo’s UK ethical compliance lead Isobel Gay tells HBW Insight in this exclusive interview.